Next review due: 5 Jul 2027 5 Jul 2024 | Latest version Last updated by Dr Colin Tidy, MRCGP Peer reviewed by Dr Doug McKechnie, MRCGP Ask, share, connect
It lets doctors request experimental drugs for individual patients outside of clinical trials
SURMOUNT-1 (tirzepatide, 72 weeks): Discontinuation due to AEs: 4.3% (5 mg), 7.1% (10 mg), 6.2% (15 mg) vs 2.6% placebo Key characteristics: GI events occur primarily during dose escalation The GIP component does not appear to add substantial GI burden beyond GLP-1 effects Pooled SURMOUNT-1 to -4 analysis showed treatment discontinuation due to GI AEs ranged from 1.0% to 10.5% Retatrutide# Retatrutide adds glucagon receptor agonism to GLP-1 and GIP, creating a triple agonist
Deoxynivalenol impairs hepatic and intestinal gene expression of selected oxidative stress, tight junction and inflammation proteins in broiler chickens, but addition of an adsorbing agent shifts the effects to the distal parts of the small intestine
Incorporating these products into our lives, even for a short while, allows us to report back to you about things like taste and efficacy, albeit at a subjective, anecdotal level
FOXO4-DRI's potential therapeutic applications are vast and varied
